LONDON, UK: SkinBioTherapeutics plc (AIM: SBTX) has entered into an agreement to acquire the issued share capital of Dermatonics Limited, a specialist in innovative topical and dermatological products in the skincare/woundcare space. The initial consideration is £1.68 million plus £1.25 million earn-out over three years, in a cash-free and debt-free acquisition. Completion will take place…